The 3 linked references in paper I. Yavelov S., И. Явелов С. (2016) “ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ ПРЯМОГО ДЕЙСТВИЯ В ПРОФИЛАКТИКЕ ИНСУЛЬТА У БОЛЬНЫХ С НЕКЛАПАННОЙ ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ В ПОВСЕДНЕВНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ: ФАКТЫ О РИВАРОКСАБАНЕ // EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN THE PREVENTION OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN EVERYDAY CLINICAL PRACTICE: FACTS ABOUT RIVAROXABAN” / spz:neicon:aterotromboz:y:2016:i:1:p:69-80

  1. Nguyen E, White CM, Patel MR, Fields LE, Peacock WF, Crivera C, Coleman CI. Doses of Apixaban and Rivaroxaban Prescribed in Real-World United States Cardiology Practices Compared to Registration Trials. Current Medical Research and Opinion, 2016. Doi: 10.1185/03007995.2016.1170672.
  2. Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace, 2016, doi:10.1093/europace/euv421.
  3. Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S, Sahin K, Titt L, Beyer-Westendorf J. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost, 2016, 115: http://dx.doi.org/10.1160/TH15-10-0840.